Evidence map›Paper›PMID 42884133›Full record

ArticleInternational journal of molecular sciences2026

Meta-Inflammation in Type 2 Diabetes Mellitus: Theoretical, Methodological, and Clinical Aspects.

Yulia Zhuravleva, Evgenii Gusev

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yulia ZhuravlevaInstitute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences, 620078 Ekaterinburg, Russia.ORCID 0000-0003-3266-0954
Evgenii GusevInstitute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences, 620078 Ekaterinburg, Russia.ORCID 0000-0002-7145-2376

Funding

Institute of Immunology and Physiology 122020900136-4
6 · The paper itself

Abstract

Currently, there is no doubt that insulin resistance (IR) in prediabetes and type 2 diabetes mellitus (T2DM) is associated with chronic systemic metabolic inflammation (SMI). SMI is typically considered a form of low-grade systemic inflammation (LGSI). At the same time, one cannot rule out the possibility of the transformation of LGSI into more pronounced forms of chronic systemic inflammation (ChSI), typical of systemic autoimmune diseases and characterized by a high severity of systemic inflammatory response (SIR). The aim of this research is to assess the pathogenetic role of SMI as a general pathological process in the pathogenesis of prediabetes and T2DM, as well as differentiating SMI into LGSI and ChSI. The study included two main groups-T2DM (

Indexed as

Diabetes Mellitus, Type 2InflammationAdultAgedBiomarkersC-Reactive ProteinCytokinesFemaleHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedPrediabetic StateBiomarkersC-Reactive ProteinCytokineschronic systemic inflammationlow-grade systemic inflammationmetabolic syndromeprediabetessystemic metabolic inflammationtype 2 diabetes mellitus

Identifiers

PMID42884133
PMCPMC13665223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.